About ani pharmaceuticals - ANIP
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
ANIP At a Glance
ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette, Minnesota 56623
| Phone | 1-218-634-3500 | Revenue | 883.37M | |
| Industry | Biotechnology | Net Income | 71.37M | |
| Sector | Health Technology | 2025 Sales Growth | 43.783% | |
| Fiscal Year-end | 12 / 2026 | Employees | 970 | |
| View SEC Filings |
ANIP Valuation
| P/E Current | 22.323 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.746 |
| Price to Sales Ratio | 1.897 |
| Price to Book Ratio | 3.285 |
| Price to Cash Flow Ratio | 9.05 |
| Enterprise Value to EBITDA | 11.638 |
| Enterprise Value to Sales | 2.275 |
| Total Debt to Enterprise Value | 0.313 |
ANIP Efficiency
| Revenue/Employee | 910,686.598 |
| Income Per Employee | 73,581.443 |
| Receivables Turnover | 3.143 |
| Total Asset Turnover | 0.649 |
ANIP Liquidity
| Current Ratio | 2.707 |
| Quick Ratio | 2.193 |
| Cash Ratio | 1.06 |
ANIP Profitability
| Gross Margin | 51.014 |
| Operating Margin | 9.196 |
| Pretax Margin | 10.844 |
| Net Margin | 8.08 |
| Return on Assets | 5.24 |
| Return on Equity | 15.115 |
| Return on Total Capital | 6.106 |
| Return on Invested Capital | 6.495 |
ANIP Capital Structure
| Total Debt to Total Equity | 116.193 |
| Total Debt to Total Capital | 53.745 |
| Total Debt to Total Assets | 43.619 |
| Long-Term Debt to Equity | 112.625 |
| Long-Term Debt to Total Capital | 52.094 |